Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
- 1 January 2020
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 241, 117152
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathyNature Reviews Nephrology, 2011
- Oxidative stress, insulin signaling, and diabetesFree Radical Biology and Medicine, 2011
- Diabetes and inflammation: Fundamental aspects and clinical implicationsDiabetes & Metabolism, 2010
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia, 2010
- Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)Mediators of Inflammation, 2010
- Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategiesDiabetic Medicine, 2009
- Microvascular Reactivity and Inflammatory Cytokines in Painful and Painless Peripheral Diabetic NeuropathyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Immune Cell Recruitment and Cell-Based System for Cancer TherapyPharmaceutical Research, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006